HUMAN MICROBIOTA AND BREAST CANCER
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17855Keywords:
breast cancer, microbiotaAbstract
Breast cancer is the leading malignancy in women worldwide. To date, much is known about the molecular subtypes of these malignant neoplasms and the mechanisms of drug resistance. Significant success has been achieved in approaches to early diagnosis, which allows identifying the tumor process in the early stages of development. Recently, the study of the influence of the human body microbiota on cancer development and the effectiveness of treatment has become an actively developing field of research. This review presents an analysis of the literature data on this issue.
References
The Integrative HMP (iHMP) Research Network Consortium The Integrative Human Microbiome Project. Nature 2019; 569: 641–49. https://doi.org/10.1038/s41586-019-1238-8
Plichta DR, Juncker AS, Bertalan M, et al. Transcriptional interactions suggest niche segregation among microorganisms in the human gut. Nat Microbiol 2016; 1: 1–6. https://doi.org/10.1038/nmicrobiol.2016.152
Lloyd-Price J, Mahurkar A, Rahnavard G, et al. Strains, functions and dynamics in the expanded Human Microbiome Project. Nature 2017; 550: 61–87. https://doi.org/10.1038/nature23889
Visconti A, Le Roy C, Rosa F, et al. Interplay between the human gut microbiome and host metabolism. Nat Commun 2019; 10: 1–10. https://doi.org/10.1038/s41467-019-12476-z
Yadav M, Verma MK, Chauhan NS. A review of metabolic potential of human gut microbiome in human nutrition. Arch Microbiol 2017; 200: 1–15. https://doi.org/10.007/s00203-017-1459-x
Cong J, Zhang X. How human microbiome talks to health and disease. Eur J Clin Microbiol Infect Dis 2018; 37: 1–7. https://doi.org/10.1007/s10096-0183263-1
Schroeder BO, Bäckhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med 2016; 22: 1079–90. https://doi.org/10.1038/nm.4185
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012; 13: 260–71. https://doi.org/10.1038/nrg3182
Olive AJ, Sassetti CM. Metabolic crosstalk between host and pathogen: sensing, adapting and competing. Nat Rev Microb 2016; 14: 1–16. https://doi.org/10.1038/nrmicro.2016.12
Dzutsev A, Badger JH, Perez-Chanona E, et al. Microbes and cancer. Annu Rev Immunol 2017; 35: 99–228. https://doi.org/10.1146/annurev-immunol-051116-052133
Eyvazia S, Vostakolaeic MA, Dilmaghanid A, et al. The oncogenic roles of bacterial infections in development of cancer. Microb Pathog 2020; 141: 1–10. https://doi.org/10.1016/j.micpath.2020.104019
Roesler BM, Rabelo-Gonзalves EMA, Zeitune JMR. Helicobacter pylori and upper gastrointestinal diseases: a review. Health 2014; 6: 263–73. https://doi.org/10.4236/health.2014.64039
Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12: 846–85. https://doi.org/10.1016/j.tranon.2019.03.003
Timbang MR, Sim MW, Bewley AF, et al. HPV-related oropharyngeal cancer: a review on burden of the disease and opportunities for prevention and early detection. Hum Vaccin Immunother 2019; 15: 1920–8. https://doi.org/10.1080/21645515.2019.1600985
Berman TA, Schiller JT. Human papillomavirus in cervical cancer and oropharyngeal cancer: one case — two diseases. Cancer 2017; 123: 2219–29. https://doi.org/10.1002/cncr.30588
Aykut B, Pushalkar S, Chen R, et al. The fungal mycobiome promotes pancreatic oncogenesis via MBL activation. Nature 2019; 574: 264–7. https://doi.org/10.1038/s41586-019-1608-2
Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Science 2020; 368: 973–80. https://doi.org/10.1126/science.aay9189
Chekhun VF, Lukyanova NYu, Shvets YuV. Impact of microibiota on development of tumors in human. Onkologiya 2020; 22: 1–9 (in Ukrainian). https://doi.org/10.32471/oncology.2663-7928.t- 22-1-2020-g.8759
Shvets YuV, Lukyanova NYu, Chekhun VF. Human microbiota and effectiveness of cancer chemotherapy. Exp Oncol 2020; 42: 1–12. https://doi.org/10.32471/ exp-oncology.2312-8852.vol-42-no-2.14611
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 1–41. https://doi.org/10.3322/caac.21660
Ahmad A. Breast cancer statistics: recent trends. In: Breast Cancer Metastasis and Drug Resistance. Ahmad A, ed. Second Edition, Springer Nature Switzerland AG, 2019: 1–8.
Wendt C, Margolin S. Identifying breast cancer susceptibility genes — a review of the genetic background in familial breast cancer. Acta Oncol 2019; 58: 135–46. https://doi.org/10.1080/0284186X.2018.1529428
Park HL. Epigenetic biomarkers for environmental exposures and personalized breast cancer prevention. Int J Environ Res Public Health 2020; 17: 1–18. https://doi.org/10.3390/ijerph17041181
Alizadeh M, Shojaeifarb S, Nedaeiniac R, et al. Association between the microbiota and women’s cancers — Cause or consequences? Biomed Pharmacother 2020; 127: 110203. https://doi.org/10.1016/j.biopha.2020.110203
Younes JA, Lievens E, Hummelen R, et al. Women and their microbes: the unexpected friendship. Trends Microbiol 2018; 26: 16–33. https://doi.org/10.1016/j.tim.2017.07.008
Hieken TJ, Chen J, Hoskin TL, et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 2016; 6: 1–10. https://doi.org/10.1038/srep30751
Costantini L, Magno S, Albanese D, et al. Characterization of human breast tissue microbiota from core needle biopsies through the analysis of multi hypervariable 16S-rRNA gene regions. Sci Rep 2018; 8: 1–9. https://doi.org/10.1038/s41598-018-35329-z
Klann K, Williamson JM, Tagliamonte MS, et al. Microbiota composition in bilateral healthy breast tissue and breast tumors. Cancer Causes Control 2020; 31: 1–12. https://doi.org/10.1007/s10552-020-01338-5
Togo А, Dufour J, Lagier J, et al. Repertoire of human breast and milk microbiota: a systematic review. Future Microbiol 2019; 14: 623–41. https://doi.org/10.2217/fmb-2018-0317
Ojo-Okunola A, Nicol M, du Toit E. Human breast milk bacteriome in health and disease. Nutrients 2018; 10: 1–13. https://doi.org/10.3390/nu10111643
Jost T, Lacroix C, Braegger CP. Vertical mother-neonate transfer of maternal gut bacteria via breastfeeding. Environ Microbiol 2014; 16: 2891–904. https://doi.org/10.1111/1462-2920.12238
Katríona E, Lyons KE, Ryan CA, et al. Breast milk, a source of beneficial microbes and associated benefits for infant health. Nutrients 2020; 12: 1–30. https://doi.org/10.3390/nu12041039
Unar-Munguía M, Torres-Mejía G, Colchero MA, et al. Breastfeeding mode and risk of breast cancer: a dose-response meta-analysis. J Hum Lact 2017; 33: 422–34. https://doi.org/10.1177/0890334416683676
Johnson HM, Mitchell KB. Breastfeeding and breast cancer: managing lactation in survivors and women with a new diagnosis. Ann Surg Oncol 2019; 26: 3032–9. https://doi.org/10.1245/s10434-019-07596-1
Stinson LF, Sindi ASM, Cheema AS, et al. The human milk microbiome: who, what, when, where, why, and how? Nutr Rev 2021; 79: 1–18. https://doi.org/10.1093/nutrit/nuaa029
Greer FR. Origins of the human milk microbiome: a complex issue. J Nutr 2019; 149: 1–3. https://doi.org/10.1093/jn/nxz004
de Andrés J, Jiménez E, Chico-Calero I, et al. Physiological translocation of lactic acid bacteria during pregnancy contributes to the composition of the milk microbiota in mice. Nutrients 2018; 10: 14. https://doi.org/10.3390/nu10010014
Arroyo R, Martin V, Maldonado A, et al. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis 2010; 50: 1551–8. https://doi.org/10.1086/652763
Picardoa SL, Coburnb B, Hansen AR, et al. The microbiome and cancer for clinicians. Crit Rev Oncol Hematol 2019; 141: 1–12. https://doi.org/10.1016/j.critrevonc.2019.06.004
Hieken TJ, Chen J, Hoskin TL, et al. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep 2016; 6: 1–10. https://doi.org/10.1038/srep30751
Urbaniak C, Cummins J, Brackstone M, et al. Microbiota of human breast tissue. Appl Environ Microbiol 2014; 80: 3007–14. https://doi.org/10.1128/AEM.00242-14
Thyagarajan S, Zhang Y, Thapa S, et al. Comparative analysis of racial differences in breast tumor Microbiome. Sci Rep 2020; 10: 1–13. https://doi.org/10.1038/s41598-020-71102-x
Urbaniak C, Gloor GB, Brackstone M, et al. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol 2016; 82: 5039–49. https://doi.org/10.1128/AEM.01235-16
Xuan C, Shamonki JS, Chung A, et al. Microbial dysbiosis is associated with human breast cancer. PLoS One 2014; 9: 1–7. https://doi.org/10.1371/journal.pone.0083744
Komorowski AS, Pezo RC. Untapped “-omics”: the microbial metagenome, estrobolome, and their influence on the development of breast cancer and response to treatment. Breast Cancer Res Treat 2019; 179: 1–19. https://doi.org/10.1007/s10549-019-05472-w
Banerjee S, Wei Z, Tan F, et al. Distinct microbiological signatures associated with triple negative breast cancer. Sci Rep 2015; 5: 15162. https://doi.org/10.1038/srep15162
Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol 2018; 9: 951. https://doi.org/10.3389/fmicb.2018.00951
Wang H, Altemus J, Niazi F, et al. Breast tissue, oral and urinary microbiomes in breast cancer. Oncotarget 2017; 8: 88122–38. https://doi.org/10.18632/oncotarget.21490
Vaiserman A, Romanenko M, Piven L, et al. Differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. BMC Microbiol 2020; 20: 1–8. https://doi.org/10.1186/s12866-020-01903-7
Du J, Zhou N, Liu H, et al. Arsenic induces functional re-expression of estrogen receptor a by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One 2012; 7: 1–10. https://doi.org/10.1371/journal.pone.0035957
Karihtala P, Kauppila S, Soini Y, et al. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer 2011; 11: 1–6. https://doi.org/10.1186/1471-2407-11-262
Mani S. Microbiota and breast cancer. Prog Mol Biol Transl Sci 2017; 151: 217–30. https://doi.org/10.1016/bs.pmbts.2017.07.004
Saggioro А. Leaky gut, microbiota, and cancer an incoming hypothesis. J Clin Gastroenterol 2014; 48: 1–5. https://doi.org/10.1097/MCG.0000000000000255
Magne F, Gotteland M, Gauthier L, et al. The Firmicutes/Bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients 2020; 12: 1–12. https://doi.org/10.3390/nu12051474
Gunter MJ, Xie XH, Xue XN, et al. Breast cancer risk in metabolically healthy but overweight postmenopausal women. Cancer Res 2015; 75: 270–4. https://doi.org/10.1158/0008-5472.CAN-14-2317
Yang J, Tan Q, Fu Q, et al. Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications. Breast Cancer 2016; 24: 1–9. https://doi.org/10.1007/s12282-016-0734-z
Fernández MF, Reina-Pérez I, Astorga JM, et al. Breast cancer and its relationship with the microbiota. Int J Environ Res Public Health 2018; 15: 1–20. https://doi.org/10.3390/ijerph15081747
Goedert JJ, Jones G, Hua X, et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst 2015; 107: 1–5. https://doi.org/10.1093/jnci/djv147
Zhu J, Liao M, Yao Z, et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 2018; 6: 1–13. https://doi.org/10.1186/s40168-018-0515-3
Arumugam M, Raes J, Pelletier E, et al. MetaHIT Consortium, Enterotypes of the human gut microbiome. Nature 2011; 473: 174–80. https://doi.org/10.1038/nature09944
Luu TH, Michel C, Bard JM, et al. Intestinal proportion of Blautia sp. is associated with clinical stage and histoprognostic grade in patients with early-stage breast cancer. Nutr Cancer 2017; 69: 1–9. https://doi.org/10.1080/01635581.2017.1263750
Baker JM, Al-Nakkashc L, Herbst-Kralovetz MM. Estrogen–gut microbiome axis: Physiological and clinical implications. Maturitas 2017; 103: 45–53. https://doi.org/10.1016/j.maturitas.2017.06.025
Zhao H, Yu Z, Zhao L, et al. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Jpn J Clin Oncol 2016; 46: 893–902. https://doi.org/10.1093/jjco/hyw096
Liu H, Wang J, He T, et al. Butyrate: a double-edged sword for health? Adv Nutr 2018; 9: 21–9. https://doi.org/10.1093/advances/nmx009
Damaskos C, Valsami S, Konto M, et al. Histone deacetylase inhibitors: an attractive therapeutic strategy against breast cancer. Anticancer Res 2017; 37: 35–46. https://doi.org/10.21873/anticanres.11286
Biagioli M, Carino A. Signaling from intestine to the host: how bile acids regulate intestinal and liver immunity. Handb Exp Pharmacol 2019; 256: 1–14. https://doi.org/10.1007/164_2019_225
Funabashi M, Grove TL, Wang M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. Nature 2020; 582: 566–70. https://doi.org/10.1038/s41586-020-2396-4
Chen ML, Takeda K, Sundrud MS. Emerging roles of bile acids in mucosal immunity and inflammation. Mucosal Immunol 2019; 12: 851–61. https://doi.org/10.1038/s41385-019-0162-4
Fiorucci S, Biagioli M, Zampella A, et al. Bile acids activated receptors regulate innate immunity. Front Immunol 2018; 9: 1–17. https://doi.org/10.3389/fimmu.2018.01853
Costarelli V, Sanders TA. Plasma deoxycholic acid concentration is elevated in postmenopausal women with newly diagnosed breast cancer. Eur J Clin Nutr 2002; 56: 925–7. https://doi.org/10.1038/sj.ejcn.1601396
Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013; 499: 97–101. https://doi.org/10.1038/nature12347
Alasmael N, Mohan R, Meira LB, et al. Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential. Cancer Lett 2016; 370: 250–9. https://doi.org/10.1016/j.canlet.2015.10.031
Plaza-Díaz J, Álvarez-Mercado AI, Ruiz-Marín CM, et al. Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study. BMC Cancer 2019; 19: 1–9. https://doi.org/10.1186/s12885-019-5660-y
Sheetal S, Sharma D. The power of small changes: Comprehensive analyses of microbial dysbiosis in breast cancer. Biochim Biophis Acta Rev Cancer 2019; 1871: 392–405. https://doi.org/10.1016/j.bbcan.2019.04.001
Rao VP, Poutahidis T, Ge ZM, et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006; 66: 7395–400. https://doi.org/10.1158/0008-5472.CAN-06-0558
Rosean CB, Bostic RR, Ferey JCM, et al. Pre-existing commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res 2019; 79: 3662–75. https://doi.org/10.1158/0008-5472.CAN-18-3464
Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, et al. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers 2020; 12: 1–27. https://doi.org/10.3390/cancers12092465
Chen KL, Madak-Erdogan Z. Estrogen and microbiota crosstalk: Should we pay attention? Trends Endocrinol Metab 2016; 27: 752–5. https://doi.org/10.1016/j.tem.2016.08.001
Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol 2019; 116: 135–70. https://doi.org/10.1016/bs.apcsb.2019.01.001
Grandi G, del Savo MC, da Silva-Filho AL, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol 2020 13: 327–30. https://doi.org/10.1080/17512433.2020.1750365
Hamilton KJ, Hewitt CS, Arao Y, et al. Estrogen hormone biology. Curr Top Dev Biol 2017; 125: 109–46. https://doi.org/10.1016/bs.ctdb.2016.12.005
Kwa M, Plottel CS, Martin J, et al. The intestinal microbiome and estrogen receptor–positive female breast cancer. J Natl Cancer Inst 2016; 108: 1–10. https://doi.org/10.1093/jnci/djw029
Chen KL, Madak-Erdogan Z. Estrogen and microbiota crosstalk: should we pay attention? Trends Endocrinol Metab 2016; 27: 1–4. https://doi.org/10.1016/j.tem.2016.08.001
Parida S, Sharma D. The microbiome–estrogen connection and breast cancer risk. Cells 2019; 8: 1–19. https://doi.org/10.3390/cells8121642
Plottel CS, Blaser MJ. Microbiome and malignancy. Cell Host Microbe 2011; 10: 324–35. https://doi.org/10.1016/j.chom.2011.10.003
Raftogianis R, Creveling C, Weinshilboum R, et al. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 2000; 27: 113–24. https://doi.org/10.1093/ oxfordjournals.jncimonographs.a024234
Ervin SM, Li H, Lim L, et al. Redinbо. Gut microbiome–derived β-glucuronidases are components of the estrobolome that reactivate estrogens. J Biol Chem 2019; 294: 18586–99. https://doi.org/10.1074/jbc.RA119.010950
Godoy-Vitorino F. Human microbial ecology and the rising new medicine. Ann Transl Med 2019; 7: 1–9. https://doi.org/10.21037/atm.2019.06.56
Fuhrman BJ, Feigelson HS, Flores R, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab 2014; 99: 1–9. https://doi.org/10.1210/jc.2014-2222
Adlercreutz Н. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 1990; 201: 3–23.
Hill MI, Drasar BS, Aries V, et al. Bacteria and aetiology of cancer of large bowel. Gut 1969; 10: 334–5. https://doi.org/10.1136/gut.10.5.334
Newman TM, Mara Z, Vitolins MZ, et al. From the table to the tumor: the role of Mediterranean and Western dietary patterns in shifting microbial-mediated signaling to impact breast cancer risk. Nutrients 2019; 11: 1–15. https://doi.org/10.3390/nu11112565
Griffiths K, Aggarwal BB, Singh RB, et al. Food antioxidants and their anti-inflammatory properties: a potential role in cardiovascular diseases and cancer prevention. Diseases 2016; 4: 1–15. https://doi.org/10.3390/diseases4030028
Shively CA, Register TC, Appt SE, et al. Consumption of Mediterranean versus Western diet leads to distinct mammary gland microbiome populations. Cell Rep 2018; 25: 47–56. https://doi.org/10.1016/j.celrep.2018.08.078
Schirmer M, Smeekens SP, Vlamakis H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 2016; 167: 1125–36. https://doi.org/10.1016/j.cell.2016.10.020
Sender R, Fuchs S, Milo R. Are we really wastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164: 337–40. https://doi.org/10.1016/j.cell.2016.01.013
Baker JM, Chase DM, Herbst-Kralovetz MM. uterine microbiota: residents, tourists, or invaders? Front Immunol 2018; 9: 1–12. https://doi.org/10.3389/fimmu.2018.00208
Ploton MC, Abakka S, Amouyal E, et al. The lung microbiota. Arch Pediatr 2017; 24: 667–74. https://doi.org/10.1016/ j.arcped.2017.04.007
Dhar D, Mohanty A. Gut microbiota and Covid-19 — possible link and implications. Virus Res 2020; 285: 198018. https://doi.org/10.1016/j.virusres.2020.198018
He Y, Wang J, Li F, et al. Main clinical features of COVID-19 and potential prognostic and therapeutic value of the microbiota in SARS-CoV-2 infections. Front Microbiol 2020; 11: 1302. https://doi.org/10.3389/fmicb.2020.01302
Yeoh YK, Zuo T, Chung-Yan-Lui G, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70: 698–706. https://doi.org/10.1136/gutjnl-2020-323020
Dai M, Liu D, Liu M et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov 2020; 10: 783–91. https://doi.org/10.1158/2159-8290.CD-20-0422
Lasagna A, Zuccaro V, Ferraris E, et al. COVID-19 and breast cancer: may the microbiome be the issue? Future Oncol 2020; 17: 123–4. https://doi.org/10.2217/fon-2020-0764
Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease. FEBS J 2020; 287: 1–55. https://doi.org/10.1111/febs.15217
Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 1–11. https://doi.org/10.1186/s13073-016-0307-y
Bashiardes S, Godneva A, Elinav E, et al. Towards utilization of the human genome and microbiome for personalized nutrition. Curr Opin Biotechnol 2018; 51: 57–63. https://doi.org/10.1016/j.copbio.2017.11.013
Barratt MJ, Lebrilla C, Shapiro H-Y, et al. The gut microbiota, food science, and human nutrition: a timely marriage. Cell Host Microbe 2017; 22: 134–41. https://doi.org/10.1016/j.chom.2017.07.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
